All those neurologists looking out for your health by alerting you to the dangers of treatment for CCSVI have overlooked the adverse event data for the drugs they prescribe day in and day out.

Adverse Events, a company that analyzes the FDA data and flags drugs whose adverse event reports indicate that they warrant more attention highlights two MS drugs as ones that should be high on the FDA radar:

• Aubagio (teriflunomide)


• Tecfidera (Dimethyl Fumarate)

Almost more interesting is that of all classes of drugs, Adverse Events singles out MS drugs with a special table because they all score so highly in the Adverse Event scoring system for drug warranting further scrutiny by the FDA.

Registration is required but a new white paper by Adverse Events is available at:

Expediting Drug Safety Using FOIA:
An Analysis of 57,000 New Unreleased FAERS Reports

http://www.adverseevents.com/foia/foia-special-report-jan2014.pdf

Here is the data from their special table on MS drugs showing what they call an Rx Score which indicates the level of concern that should be shown based on the seriousness and number of the reported adverse effects reported to the FDA:

RxScore for Multiple Sclerosis Drugs.
Novantrone (Mitoxantrone) 72.24
Ampyra (Dalfampridine) 58.13
Betaseron (Interferon Beta-1B) 54.96
Rebif (Interferon Beta-1A) 54.92
Lioresal (Baclofen) 52.00
Avonex (Interferon Beta-1A) 48.53
Aubagio (Teriflunomide) 48.36
Tysabri (Natalizumab) 47.40
Extavia (Interferon Beta-1B) 42.37
Prednisone (Prednisone) 41.60
Gilenya (Fingolimod) 31.77
Copaxone (Glatiramer Acetate) 29.00
Tecfidera (Dimethyl Fumarate) 11.23